TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Highlights: LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum combined unit commitment will be nego
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-29 3:05 AM EDT | TempraMed Technologies Ltd.
TempraMed Announces Upsize to Offering
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering wil
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:49 PM EDT | TempraMed Technologies Ltd.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 20,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.03 per Unit for gross proceeds of up to $600,000. Each Unit consists of one (1) common share of the Company (each, a "Shar
Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:00 PM EDT | PreveCeutical Medical Inc.
Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders. Since assuming the role
Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:00 PM EDT | Defence Therapeutics Inc.
naia Relief Inc. Announces Strategic Partnership with Alumni-Perks to Expand Access to 24/7 Well-Being Support for Canadian University/College Alumni
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - naia Relief Inc. (TSXV: NAIA) (FSE: GU6) ("naia Relief" or the "Company"), a workplace well-being, resilience and performance company, is pleased to announce a strategic partnership with Alumni-Perks, an always-on engagement platform connecting Canadian colleges and universities with their alumni through exclusive benefits, events, stories and community-driven content. Through the partnership, naia Relief and
2026-09-28 7:00 AM EDT | Naia Relief Inc.
WELL Health Subsidiary WELLSTAR Announces Conditional Approval for TSXV Listing and Files Filing Statement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-09-28 6:00 AM EDT | WELL Health Technologies Corp.
Vector Science and Therapeutics Corp. Issues Options
Mequon, Wisconsin--(Newsfile Corp. - September 25, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors has approved the grant of 150,000 stock options (the "Options") to an Officer of the Company in accordance with the Company's stock option plan. The Options vest in 25% tranches over a three year period, have an exercise price of C$1.80 and are exercisable for a period of five years from the
2026-09-25 5:52 PM EDT | Vector Science and Therapeutics Corp. (formerly OpenSesame Acquisition Corp.)
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Toronto, Ontario--(Newsfile Corp. - September 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research with
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-25 8:48 AM EDT | Rhelion Life Sciences Corp.
Izotropic Announces Non-Brokered Private Placement
British Columbia and Casablanca, Morocco--(Newsfile Corp. - September 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the intention to complete a non-brokered private placement (the "Offering") with of 750,000 units of the Company with a st
2026-09-25 8:00 AM EDT | Izotropic Corporation
Cheelcare Announces First Quarter Fiscal 2027 Financial Results
Markham, Ontario--(Newsfile Corp. - September 25, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced its financial results for the three months ended July 31, 2026. All figures are in CAD unless otherwise noted. Operational Highlights (Three Months Ended July 31, 2026) Companion reimbursement and market access: The Company continued to advance Companion's U.S. comm
2026-09-25 8:00 AM EDT | Cheelcare Inc.
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 10, 2026 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors and in favor of resolutions amending the c
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-24 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Tersis Technologies Hosts Private Climate Week Salon in New York
New York, New York--(Newsfile Corp. - September 24, 2026) - Tersis Technologies, Inc. (OTCID: TERS) ("Tersis" or the "Company"), a clean technology company advancing waste-to-value and circular infrastructure solutions, today announced it is hosting "From Waste to Watts," a private, invitation-only salon in Manhattan this evening, Thursday, September 24, 2026, during the United Nations General Assembly (UNGA) and Climate Week NYC.
Agriculture, Énergie, Énergies de substitution, Santé
2026-09-24 9:24 AM EDT | Tersis Technologies Inc.
Orange Insurance Services Commences Writing Policies and Exceeds Agency Growth Goals
Chicago, Illinois--(Newsfile Corp. - September 24, 2026) - Orange Underwriters, LLC DBA Orange Insurance Services ("Orange"), a technology-driven managing general agency specializing in Florida non-standard personal automobile insurance, today announced that it is actively writing insurance policies in Florida, marking a significant milestone in the company's transition from development and market launch to active insurance operations. Orange also announced that its independent agency d
2026-09-24 9:00 AM EDT | HPN Holdings, Inc.
Rise Nano Optics to Sponsor INVISION MATCH! 2026, Connecting SpectraGuard with Leading Independent Eye Care Practices
Vancouver, British Columbia--(Newsfile Corp. - September 24, 2026) - Rise Nano Optics Ltd. (CSE: EYE) (OTCQB: RNOLF) (FSE: U9Y) ("Rise" or the "Company"), a health technology company advancing vision care through patented nanotechnology lens solutions, today announced that it will participate as a sponsor of INVISION MATCH! 2026, an invite-only industry event designed to connect leading independent optometry practice owners with innovative optical
2026-09-24 7:00 AM EDT | Rise Nano Optics Ltd.
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
Highlights TempraMed and TEM Consulting International S.A. execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets. The amended framework adds VIVI Med™ to the covered product portfolio, alongside VIVI Cap™ and VIVI Epi™. TempraMed received an additional commercial order from TEM, expected to be fulfilled by the end of September 2026. Initial extended-territ
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-24 2:55 AM EDT | TempraMed Technologies Ltd.
Hemostemix Non Brokered Private Placement
Calgary, Alberta--(Newsfile Corp. - September 23, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is filing a Form 4B to obtain price protection for the closing of the third tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026, to raise $1,000,000. Each Unit consists of one common share in the capital of the Company (a "Common Share") and
Biotechnologies, Pharmaceutique, Santé
2026-09-23 4:10 PM EDT | Hemostemix Inc.
Unbuzzd Wellness Appoints Michael "Zappy" Zapolin as CEO to Lead Innovative, Clinically Validated Alcohol Metabolism Accelerant
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM ("unbuzzd") - the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin ("Zappy") as CEO. This marks a pivotal milestone in the Company. His mandate includes finan
2026-09-23 4:00 PM EDT | Unbuzzd Wellness Inc.
Restart Life Sciences Launches HC Protein+ Products Online and Advances AI-Driven E-Commerce Strategy
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the commercial online launch of its new HC Protein+ product line through Holy Crap Foods Inc. ("Holy Crap") direct-to-consumer e-commerce platform at www.holycrap.com. The launch represents another milestone in the Company's previou
2026-09-23 11:23 AM EDT | Restart Life Sciences Corp.
HarmonyRx Appoints Daniel Frisbie as Chief Financial Officer
New York, New York--(Newsfile Corp. - September 23, 2026) - HarmonyRx, a transparent, clinically driven pharmacy benefits organization, today announced the appointment of Daniel Frisbie, as Chief Financial Officer. In this role, Frisbie will lead the company's financial strategy, accounting operations, financial planning and reporting while supporting HarmonyRx's continued growth and long-term strategic objectives. Frisbie brings extensive experience in public accounting, financial repo
2026-09-23 9:15 AM EDT | HarmonyRx
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the Sheraton Valley Forge Hotel in King of Prussia, Pennsylvania. Robert Bitter
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-23 7:00 AM EDT | Phio Pharmaceuticals Corp.